Sales Success with Lyprinol®

PCSO-524TM Lipid-Complex

Tony Jacobs and Simon Barryon Behalf of

Enliten Healthcare Ltd

The Stabilised and Patented NZ Green Lipped Mussel

CO2 Supercritical non-polar lipid extract oil

Safe Treatment with Lyprinol for

– Ostheo-Arthritis– Rheumatoid Arthritis (also in

conjunction with base medication)– Asthma and Bronchial Constriction – Chronic Inflammation due to:

• Ageing• Sports

– Natural Anti-Inflammatory– No Side Effects– Complimentary to existing treatments

Contents of Lyprinol– PCSO-524TM Lipid-Complex 50 mg (Oil from NZ Green Lipped Mussels)

– Pharma Olive oil 100 mg– Vitamin E (d-α-tocopherol) 0.225 mg– Soft Gel Capsule (Bovine Gelatine)

• Contains only the Lipids = Active Substance

• (5% of the dried mussel powder) • 105 to 1 DER concentration

Lyprinol driven by Studies

–Over 30 Studies to date–4 studies about to be published in Peer Journals–4 studies are still on going–Annual Sales Growth of +30%

Works by Competive Inhibition of Cox and Lox

Jacek Szechinski, 2011• Comparison of the effectiveness of Lyprinol

versus Fish Oil, same dose of 200mg per day• 50 Patients, double blind• Duration 3 months• No side effects for Lyprinol• Pain reduction starting after 4 weeks

Recently Completed Studies

•New Zealand Lyprinol® Juvenile Asthma Study.  Single center, randomized, double-blind, placebo-controlled comparative study of 85 children between 6 and 13 years. Significant Improvement 

•Endurance Sport Protocol, Cologne, Germany.  To be published in the online British Sports Medicine Journal in MayDemonstrated Pain Relief

•Osteoarthritis Study, Poland.  Published in the Special Issue 'Marine Compounds and Inflammation' of the peer-reviewed scientific Marine Drugs journal •Demonstrated reduced arthritis-related pain by 89%, with 91% of participants reporting an improved quality of life.

•Exercise Induced Bronchial Constriction (EIBC), Indiana, USA.Study completed and been accepted for publication in the Medical Respiratory Journal.Demonstrated significant reduction of EIBC symptons. Reduced use of inhalers by 83%. Improved lung function of 59% after just 3 weeks.

Studies still in Progress• ADHD/Behavioural Study, Swinburne University, Melbourne, Australia. 

An 8 week phase II/III double-blind, placebo-controlled, cross-over study will test Lyprinol® with placebo (capsules) in 150 children/adolescents with ADHD symptoms, aged between 7 and 13 years old.  Expected to be competed in October

• Elite Sports Muscle Soreness Trial, Indiana, USA.Being conducted by leading Physiology Faculty in US for élite Sports competition.  Expected to be completed in November 

• Effects Of PCSO-524® On Arterial Plaque Formation, Charité Medical University, Berlin, Germany.  This study uses the latest laser measurement technology, ellipsometry, to identify and classify the inhibitory effects of compounds, in this case PCSO-524® relative to arterial plaque formation.   Expected to be completed in July  

• Endothelial Functionality and synergy with polyphenols, NIH BethsedaA five stream and placebo controlled study funded by the NIH. Due to be completed by December

Sales

• Australia sells approximately 7,600 pack sales of Lyprinol per month

• We have a much larger potential market here in the UK. The UK has built from only word-of-mouth and recommedation to around 2,000 packs per month through direct sales. We expect to see signifcant increase with the latest research PR activity, and the right partners!